Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Jacques Kiladjian

Showing results (21-30 of 209) with videos related to

Pageof 21
Sort By:
The Hematology Journal : the Official Journal of the European Haematology Association|May 24, 2003
Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapyJean-Jacques Kiladjian, Claude Gardin, Michel Renoux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2011
Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980Jean-Jacques Kiladjian, Sylvie Chevret, Christine Dosquet, et al.
British Journal of Haematology|June 10, 2024
Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literatureHannah Goulart, Lucia Masarova, Ruben Mesa, et al.
Current Hematologic Malignancy Reports|August 6, 2016
Social Media and Myeloproliferative Neoplasms (MPN): Analysis of Advanced Metrics From the First Year of a New Twitter Community: #MPNSMNaveen Pemmaraju, Audun Utengen, Vikas Gupta, et al.
Current Hematologic Malignancy Reports|November 7, 2017
Rare Cancers and Social Media: Analysis of Twitter Metrics in the First 2 Years of a Rare-Disease Community for Myeloproliferative Neoplasms on Social Media-#MPNSMNaveen Pemmaraju, Audun Utengen, Vikas Gupta, et al.
European Journal of Haematology|October 15, 2013
Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in FranceJérôme Rey, Jean-François Viallard, Karim Keddad, et al.
Seminars in Thrombosis and Hemostasis|July 1, 2006
Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemiaJean-Jacques Kiladjian, Jean-Didier Rain, Jean-Francois Bernard, et al.
Current Drug Targets|December 15, 2010
Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectivesHans Carl Hasselbalch, Thomas Stauffer Larsen, Caroline Hasselbalch Riley, et al.
Therapeutic Advances in Hematology|March 27, 2026
Ruxolitinib treatment in patients with polycythemia vera reduces <i>JAK2</i> variant allele frequency and improves symptom burden and hematocrit controlClaire N Harrison, Jean-Jacques Kiladjian, J E Hamer-Maansson, et al.
Haematologica|January 26, 2019
Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic reviewJean-Christophe Ianotto, Natalia Curto-Garcia, Marie Lauermanova, et al.
Pageof 21

Showing results (21-30 of 209) with videos related to

Sort By:
Pageof 21
The Hematology Journal : the Official Journal of the European Haematology Association|May 24, 2003
Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapyJean-Jacques Kiladjian, Claude Gardin, Michel Renoux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2011
Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980Jean-Jacques Kiladjian, Sylvie Chevret, Christine Dosquet, et al.
British Journal of Haematology|June 10, 2024
Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literatureHannah Goulart, Lucia Masarova, Ruben Mesa, et al.
Current Hematologic Malignancy Reports|August 6, 2016
Social Media and Myeloproliferative Neoplasms (MPN): Analysis of Advanced Metrics From the First Year of a New Twitter Community: #MPNSMNaveen Pemmaraju, Audun Utengen, Vikas Gupta, et al.
Current Hematologic Malignancy Reports|November 7, 2017
Rare Cancers and Social Media: Analysis of Twitter Metrics in the First 2 Years of a Rare-Disease Community for Myeloproliferative Neoplasms on Social Media-#MPNSMNaveen Pemmaraju, Audun Utengen, Vikas Gupta, et al.
European Journal of Haematology|October 15, 2013
Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in FranceJérôme Rey, Jean-François Viallard, Karim Keddad, et al.
Seminars in Thrombosis and Hemostasis|July 1, 2006
Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemiaJean-Jacques Kiladjian, Jean-Didier Rain, Jean-Francois Bernard, et al.
Current Drug Targets|December 15, 2010
Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectivesHans Carl Hasselbalch, Thomas Stauffer Larsen, Caroline Hasselbalch Riley, et al.
Therapeutic Advances in Hematology|March 27, 2026
Ruxolitinib treatment in patients with polycythemia vera reduces <i>JAK2</i> variant allele frequency and improves symptom burden and hematocrit controlClaire N Harrison, Jean-Jacques Kiladjian, J E Hamer-Maansson, et al.
Haematologica|January 26, 2019
Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic reviewJean-Christophe Ianotto, Natalia Curto-Garcia, Marie Lauermanova, et al.
Pageof 21